What fantastic news in the fight against obesity! Looking forward to making continuous advancements in metabolic research for conditions like NAFLD and MASLD.
Breaking News: The Treat and Reduce Obesity Act has passed the Ways and Means Committee! We extend our thanks to Chairman Congressman Jason Smith and all committee members who voted in favor. This legislation is a crucial first step in our ongoing fight against obesity, a major contributor to nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD). This milestone is not just a win in the battle against obesity but also a beacon of hope for millions struggling with associated health conditions. Join us as we continue to push for meaningful change: https://alf.social/sys
Excitement for advancements in metabolic research
- Software solutions' impact on metabolic research
- Streamlined software engineering for field advancements
- CytoCync's role in HealthTech, BioTech, MedTech, PharmaTech
- Encouragement for discussing software's role in tackling obesity and related conditions
- Assistant's purpose: generating s for CytoCync
Breaking News: The Treat and Reduce Obesity Act has passed the Ways and Means Committee! We extend our thanks to Chairman Congressman Jason Smith and all committee members who voted in favor. This legislation is a crucial first step in our ongoing fight against obesity, a major contributor to nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD). This milestone is not just a win in the battle against obesity but also a beacon of hope for millions struggling with associated health conditions. Join us as we continue to push for meaningful change: https://alf.social/sys
This year's #WorldKidneyDay theme is "Kidney Health for All - Advancing Equitable Access to Care and Optimal Medication Practice." At Boehringer Ingelheim, we understand the importance of increasing disease awareness and advancing access to treatment.
The cardiovascular, renal, and metabolic (CRM) system connects the kidneys to the heart, liver, and metabolism. Slowing the progression of #ChronicKidneyDisease has a positive impact on reducing the overall risk of developing associated conditions such as heart failure, obesity, or liver diseases.
Remember, it takes two people - you and a doctor - and two tests - blood and urine - to detect CKD. Frequent connection with your doctor and regular screening are key to detecting kidney disease and potentially reducing serious complications. Let's work together towards #KidneyHealthForAll#LifeForward.
🚨 Understanding Alcohol-Related Liver Disease: A Growing Health Concern 🚨
Alcohol-related liver disease (ARLD) is now the leading cause of death linked to excessive drinking, often undetected until too late. Recent findings show a 39% rise in ARLD deaths, affecting more men, women, and younger adults than ever. The disease progresses from fatty liver to inflammation, and potentially to fatal cirrhosis.
Key takeaways:
- Risk increases with heavy drinking: more than 7 drinks/week for women, 14 for men.
- Early detection is vital, yet early stages often show no symptoms.
- Cutting out alcohol can reverse early-stage damage; ongoing support is crucial.
Let's prioritize liver health and awareness. If concerned, seeking medical advice early can make all the difference. 🍃
#LiverHealth#AlcoholAwareness#HealthFirsthttps://lnkd.in/eWFWyrEg
Today is #WorldKidneyDay. This year the theme is "Kidney Health for All - Advancing Equitable Access to Care and Optimal Medication Practice." At Boehringer Ingelheim, we understand the importance of increasing disease awareness and advancing access to treatment.
The cardiovascular, renal, and metabolic (CRM) system connects the kidneys to the heart, liver, and metabolism. Slowing the progression of #ChronicKidneyDisease has a positive impact on reducing the overall risk of developing associated conditions such as heart failure, obesity, or liver diseases.
Remember, it takes two people - you and a doctor - and two tests - blood and urine - to detect CKD. Frequent connection with your doctor and regular screening are key to detecting kidney disease and potentially reducing serious complications. Let's work together towards #KidneyHealthForAll#LifeForward.
Many of us have been lucky and indeed privileged to have known and be inspired by Vincent Marks. Others can get inspiration by reading about his work and life story. Vincent was one of the great pioneers of islet and incretin research of his generation who amongst other things helped lead the way to GLP-1 mimetics which are now on the cusp of transforming the treatment of both diabetes and obesity.
https://lnkd.in/eBnTxAHW
On this World Liver Day, let's take a moment to reflect on the importance of liver health. Let's pledge to educate ourselves and others about the risk factors and symptoms of liver diseases. Let's advocate for access to preventive measures, early detection, and effective treatments.
Together, we can raise awareness, promote healthy lifestyles, and support research towards a world where liver diseases are no longer a silent epidemic. Cheers to a healthier future for all, starting with our livers. #WorldLiverDay#AfricurePharma#wellness#Support#africurepedia#Awareness#Pharmaceuticals#Wellness
Superb science. Will get the Nobel Prize. However, from a public health standpoint, probably around 80% of type 2 diabetes and obesity are due to our industrialized foods diet, and would go away with better dietary and lifestyle options, not relying on medications. In my own field of mental health, probably 80% of depressions are due to social determinants, and would go away with better psychological support and lifestyle improvements, not relying on antidepressants. We need to move over the next decade from precision medicine to precision health, with early detection of drift and targeted bio-socio-psychological interventions. Better for individuals, their families, their employers, and society as a whole. To be clear, am not anti- pharmacology, that is in fact my area of expertise. Am very much in favor of medications (that are matched to the right patients), but am even more in favor of comprehensive solutions. Solve the upstream.
Thirty years ago, diabetes was declared as an epidemic in the United States. At the same time, a rise in obesity was sweeping the nation. While treatment development for diabetes skyrocketed, it took decades before obesity was even thought of, and treated as, a disease.
Not everyone who is considered overweight or obese has associated health issues. But for millions of Americans, excess weight is linked to increased risks of numerous negative health effects including type 2 diabetes, hypertension, heart disease, fertility issues, and stroke.
Researchers like Richard DiMarchi wondered why so few were tackling treating excess body weight as the root cause of these associated diseases.
For his role in advancing our understanding of the GLP-1 agonist class of drugs as a treatment option for obesity, DiMarchi, alongside Lotte Bjerre Knudsen, received this year's AAAS Mani L. Bhaumik Breakthrough of the Year Award.
At Boehringer Ingelheim, we have an ambition to get more people talking about the connections between cardiovascular, renal and metabolic (CRM) diseases. Obesity, for example, is a metabolic disease which can impact the organs of the CRM system, including the liver.
This #WorldObesityDay we’re supporting the European Coalition for People Living with Obesity and the World Obesity Federation in raising awareness of this chronic metabolic disease and how it is interconnected with other diseases.
By talking about obesity and its connections both in the body and in society, we can better understand and support people living with these conditions. By educating others about the ways CRM conditions interact, we can help reduce stigma for the people living with them.
We're committed to developing meaningful partnerships with organisations that share this vision.
Learn more: https://lnkd.in/eWJqxqDV#LifeForward
Primary Biliary Cholangitis #PBC is an autoimmune liver disease affecting the bile ducts. With symptoms ranging from fatigue to severe liver damage, PBC poses a significant health concern if left untreated. However, despite its impact, PBC remains relatively unknown, affecting around 25 in 100,000 people in the UK, 90% of whom are women.
💊 There's no cure for PBC, but there are treatments that can slow the progression of the disease. Ongoing PBC clinical trials aim to improve therapeutic options.
🔍 Unfortunately one hurdle in PBC trials is the low diagnosis rates. Many people who have PBC are undiagnosed due to the subtle symptoms and limited awareness. This diagnostic delay not only affects patient wellbeing but also the recruitment process for clinical trials.
🩸 Existing blood tests could hold the key to identifying those at risk, but the system lacks easy accessibility. An efficient, searchable system could revolutionize PBC trials by swiftly pinpointing potential participants based on critical markers in blood tests.
Addressing these challenges requires a multi-pronged approach. Improving public awareness, streamlining diagnosis processes, and implementing searchable systems are important steps toward improving care for people with PBC.
To find out how we're tackling the last issue on this list, get in touch.
#ClinicalTrials#LiverHealth#WomensHealth
Excitement for advancements in metabolic research - Software solutions' impact on metabolic research - Streamlined software engineering for field advancements - CytoCync's role in HealthTech, BioTech, MedTech, PharmaTech - Encouragement for discussing software's role in tackling obesity and related conditions - Assistant's purpose: generating s for CytoCync